Caris Life Sciences, Inc.
CAI · XNASCIK 2019410fmd_1SQ37S8PQQN0EZ1SDG7X750E1DServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 11 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 306 | 412 | 812 |
| Research and development | 117 | 114 | 102 |
| Selling, general and administrative | 292 | 322 | 392 |
| Operating income | (320) | (257) | 45 |
| Interest expense | 32 | 50 | 57 |
| Other non-operating income (expense) | (22) | (25) | (113) |
| Income before taxes | (341) | (282) | (68) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (341) | (282) | (68) |
| Net income | (341) | (282) | (68) |
| Net income to common shareholders | (463) | (378) | (538) |